Cambridge, Massachusetts, United States; Rotterdam, the Netherlands; and Shanghai, China, November 18, 2026
Harbour BioMed, a global biopharmaceutical company focused on developing innovative antibody therapeutics, has announced that China’s National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for LET003, its first artificial intelligence (AI)-enabled drug candidate. LET003 is a next-generation monoclonal antibody designed to target activin receptors ACVR2A and ACVR2B for the treatment of overweight and obesity. The regulatory milestone marks an important advancement in the company’s metabolic disease research and highlights the growing application of AI-powered drug discovery in developing innovative biologic medicines. LET003 was developed using Harbour BioMed’s proprietary Hu-mAtrIxâ„¢ artificial intelligence platform and is designed to address an important challenge in modern obesity treatment: reducing excess body fat while preserving or improving lean muscle mass. The company aims to develop a differentiated therapeutic approach that could potentially complement existing glucagon-like peptide-1 (GLP-1)-based weight-loss treatments.
LET003 Targets ACVR2A and ACVR2B to Improve Body Composition
LET003 is a dual-targeting monoclonal antibody designed to block ACVR2A and ACVR2B, two activin receptors involved in regulating muscle and fat metabolism. These receptors play important roles in maintaining muscle-fat homeostasis, making them potential therapeutic targets for metabolic diseases and obesity management. Although GLP-1-based medicines have significantly advanced obesity treatment by helping patients achieve substantial weight reduction, the accompanying loss of lean body mass remains an important clinical consideration. Preserving muscle mass is essential for maintaining physical function, metabolic health and overall body composition during weight management. By simultaneously targeting ACVR2A and ACVR2B, LET003 is designed to enhance fat reduction while helping preserve or promote lean muscle mass. This mechanism could provide an additional therapeutic strategy for patients who require more comprehensive management of obesity beyond reducing body weight alone. The proposed approach focuses on improving body composition rather than weight reduction alone, potentially supporting more sustainable metabolic health outcomes.
Preclinical Studies Show Promising Combination Results
According to Harbour BioMed, preclinical investigations demonstrated encouraging pharmacological characteristics for LET003 compared with multiple competing molecules. In particular, the candidate showed favorable pharmacokinetic properties, which describe how a drug is absorbed, distributed, metabolized and eliminated by the body. One of the important findings was observed when LET003 was combined with semaglutide, a GLP-1 receptor agonist widely used in metabolic disease management. In preclinical animal models, the combination significantly enhanced fat reduction while effectively preserving lean mass. These findings suggest that combining activin receptor inhibition with GLP-1-based treatment may offer a complementary approach to obesity management. Additionally, Harbour BioMed reported that LET003 achieved lean-mass-promoting effects at a lower dose level comparable to those observed with higher doses of bimagrumab, another investigational activin receptor-targeting antibody. These results support the company’s ambition to develop LET003 as a potentially differentiated treatment candidate. However, the reported findings are based on preclinical research and have not yet established safety or efficacy in human patients. The upcoming clinical development program will be important in determining whether these benefits can be reproduced in clinical settings.
AI-Powered Hu-mAtrIx Platform Advances Drug Discovery
The acceptance of the LET003 IND application represents a major milestone for Harbour BioMed because it is the company’s first AI-enabled drug candidate developed through its proprietary Hu-mAtrIx platform. The platform integrates artificial intelligence and antibody discovery technologies to support the identification and development of next-generation therapeutic antibodies. Harbour BioMed combines its Hu-mAtrIx platform with established technologies, including Harbour Mice®, HBICE® and HCAb PLUSâ„¢, to support the discovery of fully human antibodies and multispecific therapeutic candidates. By incorporating AI-driven analysis into antibody engineering and drug discovery, the company aims to improve research efficiency, accelerate candidate development and expand its therapeutic pipeline across multiple disease areas. LET003 represents an important application of these capabilities in metabolic disease research, particularly in the development of biologics targeting obesity-related pathways.
The NMPA’s acceptance of the IND application allows Harbour BioMed to advance LET003 toward clinical development in China. IND acceptance does not mean that the drug has received marketing approval or demonstrated clinical efficacy. Human clinical studies will be required to establish its safety, tolerability, appropriate dosage and therapeutic potential. Overall, LET003 represents a promising development in AI-driven antibody discovery and next-generation obesity therapeutics. If its preclinical findings are confirmed in clinical trials, the candidate could offer a complementary approach to existing weight-loss medicines by addressing both fat reduction and lean-mass preservation.
Source: Harbour BioMed press release



